CR10985A - Progesterona para la prevencion de nacimiento pretermino espontaneo - Google Patents

Progesterona para la prevencion de nacimiento pretermino espontaneo

Info

Publication number
CR10985A
CR10985A CR10985A CR10985A CR10985A CR 10985 A CR10985 A CR 10985A CR 10985 A CR10985 A CR 10985A CR 10985 A CR10985 A CR 10985A CR 10985 A CR10985 A CR 10985A
Authority
CR
Costa Rica
Prior art keywords
progesterone
birth
pretermine
spontaneous
prevention
Prior art date
Application number
CR10985A
Other languages
English (en)
Inventor
George Creasy
Original Assignee
Columbia Lab Bermuda Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39301249&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR10985(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Columbia Lab Bermuda Ltd filed Critical Columbia Lab Bermuda Ltd
Publication of CR10985A publication Critical patent/CR10985A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un metodo para tratar o prevenir nacimiento pretermino espontaneo en mujeres embarazadas y que mejora la morbilidad y mortalidad neonatal. El metodo incluye adminsitrar a una mujer embarazada en necesidad del mismo una cantidad efectiva de una progesterona suficiente para prolongar la gestacion al reducir al minimo el acortamiento o borramiento de su cervix.
CR10985A 2007-02-06 2009-08-21 Progesterona para la prevencion de nacimiento pretermino espontaneo CR10985A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88848007P 2007-02-06 2007-02-06
US97366707P 2007-09-19 2007-09-19

Publications (1)

Publication Number Publication Date
CR10985A true CR10985A (es) 2009-10-23

Family

ID=39301249

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10985A CR10985A (es) 2007-02-06 2009-08-21 Progesterona para la prevencion de nacimiento pretermino espontaneo

Country Status (24)

Country Link
US (2) US8828981B2 (es)
EP (1) EP2117554B1 (es)
JP (2) JP5580601B2 (es)
KR (1) KR101546101B1 (es)
AR (1) AR065179A1 (es)
AU (1) AU2008212724A1 (es)
BR (1) BRPI0807203A2 (es)
CA (1) CA2677354C (es)
CL (1) CL2008000375A1 (es)
CO (1) CO6220941A2 (es)
CR (1) CR10985A (es)
ES (1) ES2596803T3 (es)
GE (1) GEP20135727B (es)
HK (1) HK1136975A1 (es)
IL (1) IL200272A (es)
MA (1) MA31200B1 (es)
ME (1) ME00930B (es)
MX (1) MX2009008409A (es)
MY (1) MY184866A (es)
NZ (1) NZ579114A (es)
PE (1) PE20081738A1 (es)
RU (1) RU2524617C2 (es)
TW (1) TWI471135B (es)
WO (1) WO2008096122A2 (es)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1535068T1 (sl) 2002-08-13 2010-07-30 N Dia Inc Naprave in postopki za odkrivanje amnijske tekočine v vaginalnih izločkih
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
EA021615B1 (ru) 2008-02-04 2015-07-30 Тева Вимен'С Хелс, Инк. Цельное интравагинальное кольцо, содержащее прогестерон, и способ изготовления и применения такого кольца
EP2334300B1 (en) 2008-09-24 2016-02-17 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Composition and method for treatment of preterm labor
GB0905964D0 (en) * 2009-04-06 2009-05-20 King S College London Marker
US20110152840A1 (en) * 2009-12-23 2011-06-23 Drugtech Corporation Methods for reducing the occurrence of preterm delivery and other pregnancy-related conditions
CA2789238C (en) * 2010-03-09 2020-05-12 Dignity Health Methods for inhibiting preterm labor and uterine contractility disorders and preventing cervical ripening
US9375437B2 (en) 2010-06-18 2016-06-28 Lipocine Inc. Progesterone containing oral dosage forms and kits
CA2813433C (en) 2010-10-27 2019-08-20 Dignity Health Trimegestone (tmg) for treatment of preterm birth
US8951996B2 (en) * 2011-07-28 2015-02-10 Lipocine Inc. 17-hydroxyprogesterone ester-containing oral compositions and related methods
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
DE102012009057A1 (de) * 2012-05-09 2013-11-14 Dr. Arabin GmbH & Co. KG Rotationspessar mit zusätzlicher Wirkstoffkomponente
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
ES2761575T3 (es) 2013-01-02 2020-05-20 Qiagen Sciences Llc Métodos para predecir el tiempo hasta el parto en una mujer embarazada
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
JP6529583B2 (ja) 2014-06-28 2019-06-12 ラボラトリオス アンドロマコ エス．エー．Ｌａｂｏｒａｔｏｒｉｏｓ Ａｎｄｒｏｍａｃｏ Ｓ．Ａ． 早産予防に有用な、長期間、持続し、継続した放出の黄体ホルモンを含む締結膣座剤
WO2016018993A1 (en) 2014-07-29 2016-02-04 Therapeuticsmd, Inc. Transdermal cream
KR101726488B1 (ko) * 2015-02-23 2017-04-13 이화여자대학교 산학협력단 바실러스 속 세균 유래 세포밖 소포체를 포함하는 임신관련 질환 치료용 조성물
US9844558B1 (en) 2015-04-30 2017-12-19 Amag Pharmaceuticals, Inc. Methods of reducing risk of preterm birth
JP2018522854A (ja) * 2015-06-22 2018-08-16 リポカイン インコーポレーテッド １７−ヒドロキシプロゲステロンエステル含有経口組成物及び関連方法
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
WO2017040243A1 (en) * 2015-08-28 2017-03-09 Kypha, Inc. Methods for predicting flare and improving treatment of patients
US10556922B2 (en) 2015-09-29 2020-02-11 Amag Pharmaceuticals, Inc. Crystalline and amorphous forms of 17-alpha-hydroxyprogesterone caproate
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
KR20180126582A (ko) 2016-04-01 2018-11-27 쎄러퓨틱스엠디, 인코퍼레이티드 스테로이드 호르몬 약제학적 조성물
EP3458070A4 (en) * 2016-05-16 2020-01-08 Amag Pharmaceuticals, Inc. PROLONGED RELEASE POLYMER COMPOSITIONS BASED ON HYDROXYPROGESTERONE CAPROATE AND METHODS OF USE THEREOF
US10935555B2 (en) 2016-12-22 2021-03-02 Qiagen Sciences, Llc Determining candidate for induction of labor
US10656164B2 (en) 2016-12-22 2020-05-19 Qiagen Sciences, Llc Screening asymptomatic pregnant woman for preterm birth
JP2018140172A (ja) * 2017-02-28 2018-09-13 株式会社Ｎｔｔドコモ データ収集装置及びデータ収集方法
US11207509B2 (en) 2017-06-15 2021-12-28 Wiesman Holdings, LLC Method and device for delivery of a solution into a body orifice
RU2657772C1 (ru) * 2017-07-06 2018-06-15 Государственное бюджетное учреждение здравоохранения Московской области "Московский областной научно-исследовательский институт акушерства и гинекологии" Министерства здравоохранения Московской области Способ профилактики гестационных осложнений у беременных с эпилепсией
US20190038637A1 (en) * 2017-08-05 2019-02-07 Eric Marchewitz Use of Hydroxyprogesterone Derivatives for Enhanced Health and Physical Performance II
SG11202003784TA (en) * 2017-10-30 2020-05-28 Carmentix Pte Ltd Biomarkers of preterm birth
RU2692932C2 (ru) * 2017-11-07 2019-06-28 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) БИОКАТАЛИЗАТОР ДЛЯ ПОЛУЧЕНИЯ 11α-АЦЕТОКСИПРОГЕСТЕРОНА
USD918388S1 (en) 2018-06-15 2021-05-04 Wiesman Holdings, LLC Solution diffusing head
JP7301326B2 (ja) * 2018-10-16 2023-07-03 公立大学法人横浜市立大学 新生児期～小児期発症の脳小血管病又はその保因者の検出方法
WO2020191297A1 (en) * 2019-03-20 2020-09-24 The Regents Of The University Of California Methods of treatment of spontaneous preterm birth
KR102157438B1 (ko) * 2019-04-16 2020-09-21 고려대학교 산학협력단 조산 진단 방법 및 키트
US20220339176A1 (en) 2019-09-23 2022-10-27 The Board Of Trustees Of The Leland Stanford Junior University Methods of Treatments to Prolong Gestation and Complications of Menstruation or Gestation
US11439588B2 (en) 2019-10-12 2022-09-13 National Research Institute For Family Planning Vaginal sustained-release drug delivery system for luteal support, method for preparation and use thereof
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
KR102482468B1 (ko) * 2020-08-11 2022-12-28 연세대학교 산학협력단 조산에 대한 정보 제공 방법 및 이를 적용한 디바이스
US20220072008A1 (en) * 2020-09-08 2022-03-10 Cedars-Sinai Medical Center Method of using progesterone receptor agonists for the treatment of covid-19
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
DE4229820C2 (de) 1992-09-07 1998-12-03 Jenapharm Gmbh Pharmazeutische Zubereitung auf Gestagen-Basis
US5830848A (en) 1992-10-09 1998-11-03 The Regents Of The University Of California Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
US5948762A (en) 1993-07-16 1999-09-07 Schering Aktiengesellschaft Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor or a nitric oxide inhibitor
US5895783A (en) 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
SK124197A3 (en) 1995-03-14 1998-06-03 Schering Ag Use of nitric oxide donors or nitric oxide inhibitors for regulating cervical dilatation and extensibility
US5910482A (en) 1996-03-19 1999-06-08 Board Of Regents, The University Of Texas System Treatment or prevention of preeclampsia, eclampsia with calcitonin gene related peptide, CGRP analog, progestational agent, nitric oxide source, and cyclooxygenase inhibitor
US6040340A (en) * 1996-05-07 2000-03-21 Schering Aktiengesellschaft Implantation rates after in vitro fertilization, treatment of infertility and early pregnancy loss with a nitric oxide donor alone or in combination with progesterone, and a method for contraception with nitric oxide inhibitors
US5744463A (en) * 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
DE69819748T2 (de) 1997-09-12 2004-09-30 Columbia Laboratories (Bermuda) Ltd. Arzneimittel zur behandlung von dysmenorrhöe und verfrühten wehen
US6248358B1 (en) 1998-08-25 2001-06-19 Columbia Laboratories, Inc. Bioadhesive progressive hydration tablets and methods of making and using the same
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
US20020031513A1 (en) 1997-11-24 2002-03-14 Shamir Leibovitz Method and pharmaceutical composition for inhibiting premature rapture of fetal membranes, ripening of uterine cervix and preterm labor in mammals
US5941888A (en) * 1998-02-18 1999-08-24 Target Therapeutics, Inc. Vaso-occlusive member assembly with multiple detaching points
IL127129A (en) * 1998-11-18 2004-06-01 Ferring Bv Method for preparation of progesterone tablets for vaginal delivery and tablets so prepared
CA2377609C (en) 1999-06-21 2009-04-21 Columbia Laboratories (Bermuda) Limited Programming ovulation
US6375970B1 (en) * 1999-07-07 2002-04-23 Andre Bieniarz Methods and materials for preterm birth prevention
US20040247674A1 (en) 2001-08-31 2004-12-09 Timo Haapakumpu Drug delivery system
FR2832065B1 (fr) * 2001-11-13 2004-11-05 Besins Int Belgique Composition pharmaceutique a base de progesterone micronisee son procede de preparation et ses utilisations
FR2842108B1 (fr) 2002-07-09 2008-05-02 Effik Composes a base d'hormone et de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
US20040266025A1 (en) 2003-02-06 2004-12-30 Durlin Hickok Screening and treatment methods for prevention of preterm delivery
US20060135496A1 (en) 2004-10-07 2006-06-22 Duramed Pharmaceuticals, Inc. Methods of hormonal treatment utilizing ascending-dose extended cycle regimens
ATE543489T1 (de) * 2005-05-26 2012-02-15 Teva Womens Health Inc Orale dosierformen mit progesteron und verwendungs- und herstellungsverfahren dafür
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth

Also Published As

Publication number Publication date
AU2008212724A1 (en) 2008-08-14
HK1136975A1 (zh) 2010-07-16
KR101546101B1 (ko) 2015-08-20
WO2008096122A2 (en) 2008-08-14
MY184866A (en) 2021-04-28
CA2677354C (en) 2015-07-07
US20080188829A1 (en) 2008-08-07
IL200272A (en) 2014-02-27
RU2524617C2 (ru) 2014-07-27
KR20090123875A (ko) 2009-12-02
MX2009008409A (es) 2009-09-16
CA2677354A1 (en) 2008-08-14
TW200902030A (en) 2009-01-16
MA31200B1 (fr) 2010-02-01
GEP20135727B (en) 2013-01-25
JP2014058529A (ja) 2014-04-03
JP2010518058A (ja) 2010-05-27
NZ579114A (en) 2012-07-27
EP2117554A2 (en) 2009-11-18
EP2117554B1 (en) 2016-07-13
AR065179A1 (es) 2009-05-20
ES2596803T3 (es) 2017-01-12
PE20081738A1 (es) 2008-11-20
TWI471135B (zh) 2015-02-01
US20090264395A1 (en) 2009-10-22
RU2009133315A (ru) 2011-03-20
CO6220941A2 (es) 2010-11-19
WO2008096122A3 (en) 2009-02-26
CL2008000375A1 (es) 2008-05-30
US7884093B2 (en) 2011-02-08
ME00930B (me) 2012-03-20
US8828981B2 (en) 2014-09-09
IL200272A0 (en) 2010-04-29
BRPI0807203A2 (pt) 2014-07-22
JP5580601B2 (ja) 2014-08-27

Similar Documents

Publication Publication Date Title
CR10985A (es) Progesterona para la prevencion de nacimiento pretermino espontaneo
DOP2012000290A (es) 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario
BR112015029056A2 (pt) composto, e pílula farmacêutica ou pastilha implantável por via subcutânea para tratar um ser humano que sofre de endometriose
ECSP20066233A (es) Compuestos y sus usos para aliviar síntomas asociados a la menopausia
UY38187A (es) Compuestos y sus usos para aliviar los síntomas relacionados con la menopausia
BR112014026340A2 (pt) sandália para hálux valgo
BR112016026510A2 (pt) Dispositivo e formulação para tratamento tópico da dor que afeta a área vulvar do órgão genital feminino
CO7111317A2 (es) Método para el tratamiento de enfermedades ginecológicas
CO2020000526A2 (es) Composición para su uso en la prevención y el traramiento de patologías del aparato cardiovascular
American College of Obstetricians and Gynecologists ACOG Committee Opinion No. 427: misoprostol for postabortion care
BR112014030984A2 (pt) composições e métodos para aumentar a eficácia de microbicidas contraceptivos
CO2017007689A2 (es) Composiciones y métodos que utilizan il-8 para aumentar la producción de leche y mejorar la salud reproductiva e inhibir la hipercetonemia en mamíferos
UA101474C2 (ru) Применение прогестерона для производства лекарственного средства
PH12015502160A1 (en) Use of specific carbohydrate systems during pregnancy for preventing fat accumulation in pregnant women
AR114011A1 (es) Uso de celiprolol para tratar el síndrome vascular de ehlers-danlos en mujeres durante el embarazo y período de periparto
BR112015015370A2 (pt) uso de uma combinação de sal e açúcar na fabricação de um medicamento utilizado para tratar a síndrome da vagina relaxada ou doença colpoxerose em um mamífero
AR114799A1 (es) Compuestos y sus usos para aliviar los síntomas relacionados con la menopausia
Silva et al. PREGNANCY OUTCOME IN JUVENILE SYSTEMIC LUPUS ERYTHEMATOSUS (JSLE): A BRAZILIAN MULTICENTER COHORT STUDY
UA41294U (ru) Способ лечения синдрома ашермана у женщин репродуктивного возраста
市田美保 et al. No increase in breast cancer risk in Japanese women taking oral contraceptives: A case-control study investigating reproductive, menstrual and familial risk factors for breast cancer.
Ayati Nausea: case report
Nayot Headache: 3 case reports
Knyazev et al. Maintenance delivery in women with a uterus operated in the aspect of insurance medicine
MD3645G2 (ro) Metodă de tratament al hemoragiilor uterine hipotonice postnatale
TH115297A (th) ระบบที่อยู่ภายในมดลูก (Intrauterine System) สำหรับการใช้ในการบำบัดทางการแพทย์